Antibiotic stewardship – a role for Managed Care

Doug Burgoyne, PharmD
CEO, Veridicus Health
GRIP: Global Respiratory Infection Partnership

Aim: To decrease inappropriate antibiotic use by developing a consistent global approach for behavioural change

- Reducing antibiotic resistance
- Securing antibiotic treatments and public health for the future
- Encouraging prescribers and patients to focus on symptom management where appropriate
Doug Burgoyne: disclosures

- Dr Burgoyne is CEO of Veridicus Health, a health and pharmacy benefits management company based in Salt Lake City, Utah.

- The consumer survey reported herein was funded by RB and conducted by a research company.

- The Global Respiratory Infection Partnership was convened by RB. All materials are sponsored by and developed in partnership with RB Healthcare. The views expressed in the materials are those of the Partnership.
Introduction

Antimicrobial resistance (AMR) is a global public health challenge that is being accelerated by the misuse of antimicrobials\(^1,2\)

Inappropriate use of antibiotics in primary care is a particular problem, with respiratory tract infections (RTIs) being one of the most common conditions for which antibiotics are prescribed\(^3\)

To create a consistent global approach to change behaviour, the **Global Respiratory Infection Partnership** (GRIP) has formulated a framework for an evidence-based, non-antibiotic approach in the management of RTIs\(^4\)

GRIP’s 1, 2, 3 approach helps healthcare professionals to:

- Take a consistent approach to the management of sore throat
- Put the patient at the centre of the consultation\(^5\)
- Direct towards symptomatic treatment, where appropriate

---

What is the incidence of AMR in the US?

At least **2 million** people in the US become infected with AMR bacteria per year.

At least **23,000** people **die as a direct result** of these infections.

---

Data from 80,089 qualifying admissions in 19 US hospitals, 2007–2010

Study evaluated percentage of bacterial isolates that were resistant to antibiotics

Implications of antibiotic resistance

- Increased risk of spread to others due to persistent infection
- Economic burden and strain on medical facilities due to prolonged illness
- Inability to treat certain infections due to lack of alternative therapies, i.e. gonorrhoea
- Death and disability in people who would have been able to continue a normal life
- Failure or increased risk of medical procedures such as surgery, C-sections
- Increased cost of treatment due to the need for more expensive therapies
- Increased risk of spread to others due to persistent infection

Antibiotic resistance
Economic considerations

Low cost of antibiotics, but high cost of resistance

Cost of antibiotics is relatively low from payer and insurance companies’ perspectives

- Little incentive to improve management

BUT cost of resistance is much higher

- In 188 patients with antibiotic-resistant infections in a single hospital, the lowest estimated attributable medical and societal cost was $13.35 million (2008 data)²

US antibiotic use for respiratory tract infections

Acute RTI-associated antibiotic prescriptions in 2005–2006:¹

- Children under 5: **779 per 1000** population
- Individuals over 5: **146 per 1000** population
- Increase in broad-spectrum antibiotics for these conditions

Of adult antibiotic prescriptions in 2007–2009:²

- The most common category was respiratory conditions, which accounted for **41%** of all visits in which antibiotics were prescribed

# US antibiotic use for respiratory tract infections

<table>
<thead>
<tr>
<th>Condition</th>
<th>Number of visits in which antibiotics were prescribed (millions)</th>
<th>Percentage of visits in which antibiotics were prescribed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute RTI for which antibiotics may potentially be indicated (e.g. pneumonia, acute sinusitis)</td>
<td>13</td>
<td>65</td>
</tr>
<tr>
<td>Acute RTI for which antibiotics are unlikely to be indicated (e.g. bronchitis, laryngitis)</td>
<td>13</td>
<td>51</td>
</tr>
<tr>
<td>Other respiratory conditions for which antibiotics are unlikely to be indicated (e.g. asthma)</td>
<td>14</td>
<td>23</td>
</tr>
<tr>
<td>All respiratory</td>
<td>40</td>
<td>38</td>
</tr>
</tbody>
</table>

Are antibiotics efficacious for RTIs?

- Vast majority of URTI symptoms do not benefit from antibiotics\(^1\)
  - \(~60\text{--}90\%\) or URTIs are non-bacterial\(^2-4\)
  - Most RTIs are self-limiting and effective non-antibiotic treatment of symptoms would reduce pressure for antibiotic use\(^5\)
  - Symptomatic relief is effective in treating URTIs\(^6-7\)

- Take sinusitis as an example:\(^3\)

  In the US, approximately 2\% of cases are bacterial

  Yet 90\% receive antibiotics from their GP

---

Patient perspectives: survey of patient behaviour in RTI consultation

Consumer survey: 33 countries, Nov/Dec 2014
- Europe, Asia, Africa, Australasia, North/South America
- 15-minute online questionnaire
- Minor ailments in five categories* in previous 12 months
  - Pain
  - Gastric, bowel
  - Foot
  - Cough, cold, respiratory
  - Eye
- 17,302 subjects responded (24,561 RTI episodes)
- Questioning:
  - Why they visited a HCP
  - Who they consulted (what kind of HCP)
  - Result of visit (recommendation, prescription – antibiotic, other)
  - If they obtained the product prescribed or recommended
  - Antibiotic use

* Subjects were also asked about blood pressure, cholesterol levels, eczema, and diabetes
US results: consultation for URTIs – why, who, outcome

Who do they consult for URTI? (n=351)
- 38% of subjects contacted a HCP
- 89% of these HCP consultations were with any physician
- 84% of these HCP consultations were with a GP

Most common reasons for consulting a healthcare professional for URTI (n=119):
- “I needed a prescription” – 36%
- “This person knows my medical history” – 28%
- “This person is the expert” – 17%
- “This is the person I trust the most” – 23%

Of subjects who consulted a physician for URTI and were prescribed a product (n=55):
- 60% were prescribed an antibiotic
## Patient perception of physician prescribing rates for URTIs – US vs. other countries

### All physicians, 33 countries

<table>
<thead>
<tr>
<th>% AB Rx*</th>
<th>18%</th>
</tr>
</thead>
</table>

### Countries

<table>
<thead>
<tr>
<th>Subjects with URTI</th>
<th>Brazil</th>
<th>Germany</th>
<th>India</th>
<th>Indonesia</th>
<th>Malaysia</th>
<th>UAE</th>
<th>UK</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>% contacted any physician</td>
<td>52%</td>
<td>33%</td>
<td>64%</td>
<td>55%</td>
<td>61%</td>
<td>57%</td>
<td>22%</td>
<td>34%</td>
</tr>
<tr>
<td>% AB Rx†</td>
<td>15%</td>
<td>10%</td>
<td>15%</td>
<td>28%</td>
<td>18%</td>
<td>17%</td>
<td>23%</td>
<td>28%</td>
</tr>
</tbody>
</table>

Rx, prescription.

*Aggregate data across all 33 countries.
†Proportion of patients consulting any physician and receiving a prescription for an antibiotic.
Patient consultation for RTIs: insights into the physician-patient interaction

- Physicians tend to over-estimate patients’ desire for an antibiotic\(^1,2\)
- Physicians may misinterpret the expectations or a patient, have limited time, or respond to patients’ pressure for antibiotics
  - These factors may lead to over-prescribing of antibiotics for respiratory disease
- Patients’ expectations are usually not directly explored
  - Reassurance, diagnosis (based on physical examination)
  - Overall advice and/or advice about pain/symptomatic relief\(^3\); this is supported by the consumer survey data
  - Information on natural course and self-limitedness of disease
- There is a key opportunity for primary care to educate, advise and reassure:
  - Physiology and duration of URTI symptoms
  - Efficacy of appropriate treatment options
  - Highlighting appropriate symptomatic treatment

GRIP activities: changing prescribing attitudes

- **CAPABILITY**
  - Ensuring HCPs have the necessary knowledge and information to practice appropriate RTI management
    - GRIP toolkit materials

- **MOTIVATION**
  - Reducing patient demand for antibiotics in RTIs indirectly changes HCP motivation to prescribe/dispense/sell
    - Patient leaflet, tear-off pad and poster

- **OPPORTUNITY**
  - Creation of an environment where prescribing in RTIs is not the norm (physical and social)
    - GRIP’s 5P framework for change

---

The GRIP 5P framework

A framework to facilitate change towards appropriate use of antibiotics

The aim is to adopt a patient-centered symptomatic management strategy

• Flexible, interlinking framework
• Adaptable across countries
• Can provide a global and regional framework for change

Success of antibiotic stewardship varies by health plan

Commercial Healthcare Maintenance Organization health plan performance on avoidance of antibiotic therapy in adults with acute bronchitis in New York

Higher scores denote better performance.


Call to action: reduce inappropriate antibiotic use

Where can Managed Care make a change?

- Educate prescribers and patients (GRIP)
- Highlight cost savings achievable with antibiotic stewardship
- Enhance use of treatment decision making tools in primary care
- Incentivise symptomatic treatment in primary care, especially for RTIs
- Enable pharmacists to issue “prescriptions” for reimbursable symptomatic OTC treatments
- Reimburse when GPs prescribe OTC products for symptomatic treatment or for patient counsel on inappropriate antibiotic use
Remove incentives for inappropriate antibiotic use

- Current financial incentives are often at odds with best clinical practice
- Need to increase use of revenue models that are not dependent on number prescriptions filled, i.e. remove financial incentives to increase volume of antibiotics prescribed
  - Administration charges vs. pricing models
- Consider how to tackle physician concern about unhappy patients who may give low satisfaction scores if they have not received a prescription for antibiotics
Incentivize development of novel antibiotics and stewardship of existing antibiotics

- Consider financial incentives for symptomatic treatment of RTIs
- Lobby for policies that introduce financial incentives (e.g. value-based reimbursement) to encourage development of novel antibiotics
- Drive development and implementation of large-scale antibiotic stewardship programmes
  - Invest in tools to support this, for example:
    - Tools making use of electronic medical records to support health plan monitoring
    - Clinical decision-making tools for primary and secondary care
    - Encourage health plan involvement/financial support of local and regional stewardship programmes
Summary and conclusions

- Antibiotic resistance is a substantial and growing global public health threat in the US\(^1,2\).
- The cost of antibiotics is relatively low from payer and insurance companies’ perspectives, but the cost and impact of antibiotic resistance is potentially crippling.
  - Consider financial incentives for symptomatic treatment of RTIs.
- The most common category for adult antibiotic prescriptions is RTIs\(^3\), despite the fact that many RTIs are non-bacterial\(^4\)–\(^6\).
- The call to action to reduce inappropriate use of antibiotics is urgent.
- Managed care can contribute to antibiotic stewardship, particularly in the field of RTIs, by providing incentives for OTC symptomatic treatment and supporting implementation of stewardship programmes.
- There is a key opportunity for primary care to educate, advise and reassure:
  - Physiology and duration of URTI symptoms.
  - Efficacy of appropriate treatment options.
  - Highlighting appropriate symptomatic treatment.